Business insights and articles written by our team of world-class professionals
Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, today announced that the Consortium for
Avulux, the maker of the only clinically proven migraine and light sensitivity lenses, and PECAA (Professional Eye Care Associates of America) are pleased to announce
Migraine is a genetic neurological disease that affects nearly 48 million people in the United States — that’s almost 1 in 5 patients in your practice.
Avulux is proud to announce formal partnerships with Opti-Port, the eye care industry’s only alliance of growth-oriented, multi-office eye care practices, and with PERC, a
Guest ContributorBradley Katz, MD, PhDMoran Eye Center Severe headache, nausea, sensitivity to light and sound, vision loss, depression, fatigue. For the nearly 48 million Americans
Partnership between Eyenavision and Avulux offers elevated patient care and accelerated practice growth opportunities for eyecare providers PITTSBURGH/MIAMI – Aug. 19, 2024 – Eyenavision and
Many ECPs have heard of FL-41 – a generic tint formulation that has been used by lens manufacturers since the early 1990s – developed for
Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, today announced that Brant Southwell has
Avulux is proud to announce our official partnership with IDOC, a service-focused alliance committed to the success of all independent-owner optometrists. As an official vendor
Log in to access Avulux marketing assets, training and education materials, and to learn about upcoming events and promotions.
Don’t have an account? Become an Avulux Authorized Provider
If you’re unable to reset your password, or can’t find your account, reach our team at sales@ecp.avulux.com.